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Rituximab for Refractory Polymyositis: An Open-label
Prospective Study
CHI CHIU MOK, LINGYIN HO, and CHI HUNG TO
ABSTRACT. Objective. To report the efficacy and toxicity of rituximab in the treatment of refractory polymyositis.
Methods.Adult patients with active polymyositis as evidenced by persistent proximal muscle weakness,
elevated creatine kinase (CK) level, and features of active myositis on electromyography who were
refractory to corticosteroids and at least 2 other immunosuppressive agents were recruited. While
immunosuppressive agents were continued, rituximab (375 mg/m2) was given by intravenous infusion
weekly for 4 consecutive weeks. Patients were followed up 4-weekly for serial assessment of muscle
power, serum muscle enzymes, physician’s and patient’s global impression of disease activity, disabili-
ty, and quality of life scores.
Results. Four patients (3 women, 1 man) were studied. The mean age was 53 ± 11 years and the mean
duration of polymyositis was 4.8 ± 3.3 years. All had persistently active myositis for at least 2 years. At
Week 28, significant improvement in the mean proximal muscle power scores and reduction in CK
levels in comparison to baseline were observed. Two patients had return of full muscle power with sig-
nificant drop in CK level. There was a trend of improvement in disability scores and both the mental and
physical components of the Medical Outcomes Study Short Form-36 Health Survey scores. Rituximab
was well tolerated.
Conclusion. Rituximab is an option to be considered in refractory polymyositis, but further controlled
trials are necessary to confirm its efficacy. (First Release August 15 2007; J Rheumatol 2007;34:1864–8)
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Polymyositis (PM) is a chronic idiopathic autoimmune
inflammatory muscle disorder that is associated with signifi-
cant morbidity and mortality1. The mainstay of treatment is
corticosteroids. However, a substantial proportion of patients
with PM are either partially responsive or refractory to corti-
costeroid treatment. Uncontrolled and small controlled trials
have demonstrated that azathioprine (AZA), methotrexate
(MTX), cyclosporine A (CSA), and intravenous immunoglob-
ulin (IVIG) are effective in inflammatory myopathies that
included polymyositis2. A number of agents such as IVIG,
cyclophosphamide (CYC), mycophenolate mofetil (MMF),
tacrolimus, CSA, etanercept, and infliximab have also been
used anecdotally with success in refractory polymyositis3.
Rituximab is a chimeric monoclonal antibody that directs
against the CD20 antigen on the surface of B cells.
Administration of rituximab leads to selective depletion of the
CD20+ B cells, leaving the stem cells and plasma cells unaf-
fected. A randomized controlled trial has shown that rituximab
is effective in rheumatoid arthritis that is refractory to MTX4.
Uncontrolled open-label trials have also demonstrated efficacy
of rituximab in the treatment of a variety of autoimmune dis-
eases such as refractory systemic lupus erythematosus,
immune thrombocytopenic purpura, autoimmune hemolytic
anemia, IgM associated polyneuropathies, and systemic vas-
culitides5. A recent open-label study demonstrated efficacy of
rituximab in the treatment of 6 patients with dermatomyositis6.
Several other case reports have described benefits of rituximab
in the management of refractory polymyositis7-9. However,
formal assessment of disability and quality of life is not avail-
able in these reports. We conducted an open-label prospective
study of the efficacy of rituximab in 4 patients with polymyosi-
tis who were refractory to conventional therapies.
MATERIALS AND METHODS
Patient recruitment. Four patients who fulfilled the following criteria were
included for this study: (1) age ≥ 18 years; (2) met the Bohan and Peter cri-
teria for definite or probable diagnosis of polymyositis10; (3) investigations
did not reveal other underlying autoimmune diseases or malignancies; (4)
active myositis as evidenced by persistent proximal muscle weakness, elevat-
ed creatine kinase (CK), and features of active myositis on electromyography
(EMG) for at least 4 months; (5) refractory to corticosteroids and at least 2
other immunosuppressive agents. Exclusion criteria were: (1) major surgery
within 8 weeks prior to study; (2) immunization with a live/attenuated vaccine
within 4 weeks prior to study; (3) active current bacterial, viral, fungal,
mycobacterial, or other infections; (4) pregnant women or lactating mothers.
Treatment protocol. Informed consent was obtained from all patients. While
immunosuppressive agents at study entry were allowed to be continued, their
dosages could not be altered throughout the study period. In addition, ritux-
imab (375 mg/m2) was given by IV infusion weekly for 4 consecutive weeks.
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Paracetamol (1000 mg) alone was routinely given as a premedication before
infusion of rituximab. Antihistamines and corticosteroids were not routinely
given as premedications, but were reserved for patients who developed aller-
gic reactions to rituximab infusion.
Clinical assessment. Patients were followed up at baseline and then 4-week-
ly until the 20th week. The following assessment was serially performed: (1)
manual muscle strength testing of the proximal (shoulder adductors and
abductors, biceps, triceps, hip flexors and extensors, hip adductors and abduc-
tors, knee flexors and extensors) and axial muscles (neck and trunk muscles)
as assessed on a 0–10 point scale11; (2) serum muscle enzymes [CK, lactate
dehydrogenase, serum glutamic-oxaloacetic transaminase (SGOT)]; (3)
physician’s global assessment of disease activity [visual analog scale (VAS)
0–10]; (4) patient’s global assessment of disease activity (VAS 0–10); (5) dis-
ability scores [Health Assessment Questionnaire (HAQ)] (baseline, Week 12
and 20); (6) quality of life [Medical Outcomes Study Short Form-36 Health
Survey (SF-36) questionnaire] (baseline, Week 12 and 20); (7) complete
blood counts, lymphocyte counts, liver and renal function tests; and (8)
adverse events related to rituximab infusion. The same physician (CHT), who
was blinded for the medical records, laboratory results, drug treatment, and
visit week number of patients, was responsible for assessing the muscle
power and physician’s global scores of the activity of myositis throughout the
study visits. A research nurse was responsible for obtaining the self-reported
questionnaire results before clinical assessment.
After completion of Week 20 assessment, we continued to follow our
patients up 4-weekly for another 2 visits for clinical muscle power and serum
muscle enzyme levels.
Statistical analyses. Unless otherwise specified, values were expressed as
mean ± standard deviation (SD). The paired Student’s t-test was used to com-
pare continuous data between baseline and various time intervals after ritux-
imab infusion. Statistical significance was defined as p values < 0.05, 2-tailed.
All statistical analyses were performed by the SPSS program (version 11.5 for
Windows XP; SPSS, Chicago, IL, USA).
RESULTS
Four patients (3 women, 1 man) were studied. The mean age
was 53 ± 11 years and the mean duration of polymyositis was
4.8 ± 3.3 years. Previous ineffective therapies included high
dose corticosteroids (n = 4), IV pulse methylprednisolone (n =
2), AZA (n = 4), MTX (n = 1), MMF (n = 4), CSA (n = 3),
tacrolimus (n = 1), and IVIG (n = 3). All of them had active
myositis at study entry as evidenced by persistent muscle
weakness and elevation of the muscle enzymes for at least 4
months, with documentation by EMG. Muscle biopsy was
performed in all patients at the time of diagnosis and 2 of them
showed histological features compatible with polymyositis. In
the other 2 patients, special staining of the muscle fibers for
glycogen was negative and their lipid content was not
increased. Examination by electron microscopy did not reveal
any inclusion or tubuloreticular bodies. Table 1 shows the
clinical characteristics and histological findings of the 4
patients studied. Anti-Jo-1 antibody was present in Patient 2
but absent in the other patients.
Changes in muscle power and muscle enzyme levels. Figures
1 and 2 show the serial changes in proximal muscle power
(mean score of the proximal muscles tested) and serum CK
levels of our patients. There was a significant improvement in
proximal muscle power at Week 28 compared to baseline (5.3
± 3.8 to 7.3 ± 3.8, respectively; p = 0.002). The drop in CK
levels also reached significance (2632 ± 1583 to 661 ± 359
U/l; p = 0.05). The treatment response of individual patients is
also summarized in Table 1. Two patients had return of full
muscle power with a significant drop in muscle enzymes
(Patients 2 and 3). The clinical improvement in these 2
patients was significant and meaningful. The other 2 patients
had reduction in muscle enzyme level, but clinical improve-
ment in muscle power was only modest (Patients 1 and 4).
Changes in disability and quality of life. Figures 3 to 5 show
the serial changes in global assessment, quality of life, and
disability scores in our patients from baseline to Week 20. A
trend of reduction in global assessment scores and HAQ
scores and improvement in both the mental and physical com-
ponents of the SF-36 scores was observed.
Changes in total lymphocyte counts. Figure 6 shows the seri-
al changes in mean total lymphocyte counts of our patients
before and after rituximab infusion. A drop in the lymphocyte
counts occurred at Week 4, followed by a gradual return of the
counts to pretreatment levels at Week 16.
Adverse events. Despite the fact that corticosteroids were not
used as premedication prior to rituximab infusion, none of our
patients experienced allergic or infusion reactions. No infec-
tive episodes or other adverse events were reported throughout
the study period.
DISCUSSION
This is a prospective study of the efficacy of rituximab in 4
patients with refractory polymyositis. Significant improve-
ment in the mean proximal muscle power scores and serum
CK levels was observed at 28 weeks as compared to baseline.
Two patients had clinically meaningful improvement in mus-
cle power with a significant drop in CK level. Moreover, there
was a trend of improvement in disability scores and quality of
life at 20 weeks after rituximab treatment. Although a control
group is lacking, the clinical improvement is unlikely to be
spontaneous because all patients had persistently active
myositis and elevated CK levels for at least 4 months before
rituximab infusion. Indeed, all patients had active myositis
refractory to multiple treatment modalities for at least 2 years
before study entry. One additional observation is that the clin-
ical response of myositis to rituximab may be delayed.
Obvious improvement in clinical muscle power and reduction
in CK level was not observed until Week 20 after treatment.
Nevertheless, rituximab was well tolerated.
Our results are in accord with those recently reported by
several independent groups6-9. Levine described improvement
in muscle strength, muscle enzymes, and skin lesions after rit-
uximab treatment (4-weekly infusions of 100 mg/m2 in 3
patients and 375 mg/m2 in the other 3) in 6 patients with
refractory dermatomyositis6. Maximum improvement in mus-
cle power only occurred at 12 to 36 weeks after treatment.
Noss, et al7 described successful use of rituximab (2 doses of
1000 mg at 2-week interval) in 3 patients with refractory
polymyositis. Decrease in muscle enzymes was observed 1
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month postinfusion, with normalization of levels ranging from
2.6 to 7.7 months. Muscle strength improved in all, with
strength returning to normal in 2 patients. Two other case
reports also described efficacy of rituximab in the treatment of
refractory dermatomyositis and polymyositis8,9.
There are limitations to our study. The sample size is small
and may have contributed to the insignificant changes of dis-
ability and quality of life scores by statistical analyses. The
adoption of the Bohan and Peter criteria for the diagnosis of
polymyositis may have led to the inclusion of patients with
inclusion body myositis in our study. Although muscle biopsy
examination did not reveal inclusion bodies in our patients, we
cannot totally exclude this possibility, especially in the 2
patients who had suboptimal response to rituximab, because
evidence of inclusion body myositis may still be missed in
biopsy samples as a result of sampling error. Finally, we did
not evaluate the CD20+ B cell count and the human anti-
chimeric antibodies in our patients, which may be factors
influencing the clinical efficacy of rituximab.
Because of publication bias, the efficacy of rituximab in
inflammatory myopathies might have been overemphasized in
the literature. Therefore, further controlled trials are needed
to confirm the clinical efficacy of the drug. However, ritux-
imab is generally well tolerated and is an option to be con-
Table 1. Clinical characteristics and treatment response of individual patients.
Age, Sex Disease Muscle Previous Therapies within Treatment Response
yrs Duration, Histological Ineffective 3 Months of
Patient yrs Findings Therapies Study Entry
1 46 F 4 Muscle fibers vary in diameter, Pred, pulse MP, Pred 5 mg/day, Drop in CK level with mild
atrophic and regenerative fibers AZA, CSA, MMF 1.5 g/day improvement in proximal muscle power
present, minimal inflammatory MMF, IVIG
cellular infiltration. Glycogen stain
negative, lipid content normal, EM
examination for tubuloreticular and
inclusion bodies negative
2 51 F 5 Variation in fiber diameter, atrophic Pred, AZA, CSA, Pred 7.5 mg/day, Normalization of muscle power and CK
and regenerating fibers present, MTX, MMF, tacrolimus
mononuclear cellular infiltration, tacrolimus, IVIG 4 mg/day
glycogen stain negative, lipid content
not increased, no fiber necrosis
3 69 M 2 Muscle fibers vary in diameter, Pred, AZA, Pred 2.5 mg/day, Normalization of muscle power and
angular atrophic fibers of random MMF MMF 2 g/day significant drop in CK level
distribution and sporadic regenerating
fibers present, endomysial
mononuclear cellular infiltration,
glycogen stain negative, lipid content
not increased
4 47 F 8 Necrotic and atrophic fibers present, Pred, pulse MP, Pred 20 mg/day, Significant drop in CK level but minimal
with regenerating fibers at various AZA, CSA, CYC, MMF 2 g/day improvement in muscle power
stages, mononuclear cellular infiltrate IVIG, MMF
in endomysium and within muscle fibers,
glycogen stain negative, EM examination
for tubuloreticular and inclusion bodies
negative
Pred: prednisolone; MP: methylprednisolone; AZA: azathioprine; CSA: cyclosporine A; MMF: mycophenolate mofetil; IVIG: intravenous immunoglobulin;
MTX: methotrexate; CK: creatine kinase.
Figure 1. Serial change in mean proximal muscle power.
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sidered in patients with inflammatory myopathies who are
refractory to multiple conventional therapeutic modalities. A
caution of the use of rituximab is the rare occurrence of ful-
minant chronic hepatitis B reactivation12 and progressive
multifocal leukoencephalopathy, probably caused by reacti-
vation of JC virus recently reported by the US Food and Drug
Administration13.
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Figure 3. Change in global assessment scores (higher scores indicated more
serious disease). p values refer to change from baseline to Week 20. VAS:
visual analog scale. Figure 4. Change in quality of life scores. p values refer to change from base-
line to Week 20. PCS: physical component score; MCS: mental component
score; Total: total SF-36 score.
Figure 2. Serial change in creatine kinase (CK) level.
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Figure 5. Change in disability scores. p = 0.29; i.e.,
change from baseline to Week 20. HAQ: Health
Assessment Questionnaire.
Figure 6. Serial change in total lymphocyte counts.
